# LY6G5C

## Overview
LY6G5C is a gene that encodes the protein lymphocyte antigen 6 family member G5C, which is part of the Ly6/uPAR family of proteins. These proteins are characterized by the presence of a LU domain, which typically adopts a three-fingered structure stabilized by disulfide bridges, similar to those found in snake venom neurotoxins (Loughner2016Organization). LY6G5C is expressed in a variety of tissues, including the testis, fetal liver, spleen, and certain immune cells, and is involved in hematopoietic cell differentiation (Loughner2016Organization). Unlike many other Ly6/uPAR family members, LY6G5C lacks a glycosylphosphatidylinositol (GPI) anchor, which influences its interactions on the cell surface (Loughner2016Organization). The gene has been implicated in several diseases, including nasopharyngeal carcinoma, Parkinson's disease, and fibromyalgia, through alterations in its methylation and expression levels, highlighting its potential role in immune and neurological pathways (Polli2020Epigenetic; HendersonSmith2019DNA; Dai2016Genetic).

## Structure
LY6G5C is a member of the Ly6/uPAR family of proteins, characterized by the presence of a LU domain. This domain typically features a three-fingered structure formed by disulfide bridges connecting conserved cysteine residues, similar to the structure found in snake venom neurotoxins (Loughner2016Organization). The LU domain in LY6G5C is stabilized by five well-conserved disulfide bridges, and the sequence of amino acids at the tips of each finger is variable, allowing for diverse interactions (Loughner2016Organization). 

The LU domain proteins, including LY6G5C, generally have a consensus sequence of 60-90 residues with specific disulfide bonds, although variations can occur (Leth2019Evolution). The molecular structure of these proteins is defined by their disulfide-bonded network and the three-fingered fold topology (Leth2019Evolution). 

LY6G5C is expressed in various tissues, including the testis, fetal liver, spleen, retina, heart, thymus, MS lesions, germinal center B cells, and carcinoid lung, and plays a role in hematopoietic cell differentiation (Loughner2016Organization). The protein is often GPI-anchored, facilitating interactions with other proteins on the cell surface (Loughner2016Organization).

## Function
LY6G5C is a member of the Ly6/uPAR family of proteins, which are characterized by the presence of a LU domain with a three-finger structure stabilized by disulfide bridges. This domain is similar to those found in snake venom neurotoxins and is involved in various intermolecular interactions (Loughner2016Organization). LY6G5C is expressed in several tissues, including the testis, fetal liver, spleen, retina, heart, thymus, and certain immune cells, such as germinal center B cells. It is associated with hematopoietic cell differentiation, although its specific molecular activities in healthy cells are not detailed (Loughner2016Organization).

Unlike many other members of the Ly6/uPAR family, LY6G5C does not have a glycosylphosphatidylinositol (GPI) anchor, which typically facilitates membrane tethering and interactions on lipid rafts (Loughner2016Organization). The expression of LY6G5C and other Ly6/uPAR proteins is often correlated with cellular differentiation and can be upregulated during inflammatory conditions or infections, suggesting a role in immune response regulation (Loughner2016Organization). However, the specific molecular processes and organismal outcomes of LY6G5C's activity in healthy human cells remain to be fully elucidated.

## Clinical Significance
The LY6G5C gene has been implicated in several diseases through alterations in its methylation and expression levels. In nasopharyngeal carcinoma (NPC), LY6G5C is found to be hypermethylated in tumor tissues compared to non-tumor tissues, suggesting a role in the epigenetic regulation of gene expression in cancer (Dai2016Genetic). In Parkinson's disease (PD), LY6G5C is identified as a differentially methylated region with five altered CpG sites, indicating its potential as a brain-specific epigenetic marker of the disease (HendersonSmith2019DNA). The gene's methylation changes in PD are associated with immune system alterations, as it is located in the major histocompatibility complex (MHC) class III region, which is linked to immune function (HendersonSmith2019DNA).

LY6G5C is also differentially methylated in fibromyalgia, a condition characterized by chronic pain, suggesting its involvement in immune response regulation in pain conditions (Polli2020Epigenetic). Additionally, LY6G5C has been recognized as a brain-specific epigenetic marker in schizophrenia, highlighting its potential role in neuropsychiatric disorders (Wockner2015Brainspecific). These findings underscore the gene's significance in various diseases, particularly those involving immune and neurological pathways.


## References


[1. (Wockner2015Brainspecific) L F Wockner, C P Morris, E P Noble, B R Lawford, V L J Whitehall, R M Young, and J Voisey. Brain-specific epigenetic markers of schizophrenia. Translational Psychiatry, 5(11):e680–e680, November 2015. URL: http://dx.doi.org/10.1038/tp.2015.177, doi:10.1038/tp.2015.177. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/tp.2015.177)

[2. (Loughner2016Organization) Chelsea L. Loughner, Elspeth A. Bruford, Monica S. McAndrews, Emili E. Delp, Sudha Swamynathan, and Shivalingappa K. Swamynathan. Organization, evolution and functions of the human and mouse ly6/upar family genes. Human Genomics, April 2016. URL: http://dx.doi.org/10.1186/s40246-016-0074-2, doi:10.1186/s40246-016-0074-2. This article has 158 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40246-016-0074-2)

[3. (Leth2019Evolution) Julie Maja Leth, Katrine Zinck Leth-Espensen, Kristian Kølby Kristensen, Anni Kumari, Anne-Marie Lund Winther, Stephen G. Young, and Michael Ploug. Evolution and medical significance of lu domain−containing proteins. International Journal of Molecular Sciences, 20(11):2760, June 2019. URL: http://dx.doi.org/10.3390/ijms20112760, doi:10.3390/ijms20112760. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms20112760)

[4. (Dai2016Genetic) Wei Dai, Hong Zheng, Arthur Kwok Leung Cheung, and Maria Li Lung. Genetic and epigenetic landscape of nasopharyngeal carcinoma. Chinese Clinical Oncology, 5(2):16–16, April 2016. URL: http://dx.doi.org/10.21037/cco.2016.03.06, doi:10.21037/cco.2016.03.06. This article has 86 citations and is from a peer-reviewed journal.](https://doi.org/10.21037/cco.2016.03.06)

[5. (Polli2020Epigenetic) Andrea Polli, Lode Godderis, Manosij Ghosh, Kelly Ickmans, and Jo Nijs. Epigenetic and mirna expression changes in people with pain: a systematic review. The Journal of Pain, 21(7–8):763–780, July 2020. URL: http://dx.doi.org/10.1016/j.jpain.2019.12.002, doi:10.1016/j.jpain.2019.12.002. This article has 41 citations.](https://doi.org/10.1016/j.jpain.2019.12.002)

[6. (HendersonSmith2019DNA) Adrienne Henderson-Smith, Kathleen M. Fisch, Jianping Hua, Ganqiang Liu, Eugenia Ricciardelli, Kristen Jepsen, Mathew Huentelman, Gabriel Stalberg, Steven D. Edland, Clemens R. Scherzer, Travis Dunckley, and Paula Desplats. Dna methylation changes associated with parkinson’s disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood. Epigenetics, 14(4):365–382, March 2019. URL: http://dx.doi.org/10.1080/15592294.2019.1588682, doi:10.1080/15592294.2019.1588682. This article has 60 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/15592294.2019.1588682)